Background-The majority of hypertriglyceridemias are diagnosed as familial combined hyperlipidemia (FCHL) and primary isolated hypertriglyceridemias. The contribution of common genetic variants in primary hypertriglyceridemias and the genetic difference between FCHL and isolated hypertriglyceridemias have not been thoroughly examined. Methods and Results-This study involved 580 patients with hypertriglyceridemias and 403 controls. Of the 37 single nucleotide polymorphisms examined, 12 located in 10 genes showed allelic and genotype frequency differences between hypertriglyceridemias and controls. The minor alleles of APOE, APOA5, GALNTN2, and GCKR variants were positively correlated with plasma triglycerides, whereas minor alleles of ADIPOR2, ANGPTL3, LPL, and TRIB1 polymorphisms were inversely associated. Body mass index, glucose, sex, rs328 and rs7007797 in LPL, rs662799 and rs3135506 in APOA5, and rs1260326 in GCKR explained 36% of the variability in plasma triglycerides, 7.3% of which was attributable to the genetic variables. LPL, GCKR, and APOA5 polymorphisms fit dominant, recessive, and additive inheritance models, respectively. Variants more frequently identified in isolated hypertriglyceridemias were rs7412 in APOE and rs1800795 in IL6; rs2808607 in CYP7A1 and rs3812316 and rs17145738 in MLXIPL were more frequent in FCHL. The other 32 single nucleotide polymorphisms presented similar frequencies between isolated hypertriglyceridemias and FCHL. Conclusions-Common genetic variants found in LPL, APOA5, and GCKR are associated with triglycerides levels in patients with primary hypertriglyceridemias. FCHL and isolated hypertriglyceridemias are probably trace to an accumulation of genetic variants predisposing to familial and sporadic hypertriglyceridemias or to hypertriglyceridemias and hypercholesterolemia in case of FCHL. (Circ Cardiovasc Genet. 2014;7:814-821.)
H ypertriglyceridemia syndromes are common and important lipid abnormalities in most countries. 1, 2 Hypertriglyceridemia is highly associated in prospective studies with the development of cardiovascular disease 3, 4 and diabetes mellitus 5, 6 although whether hypertriglyceridemia is a causal factor or an epiphenomenon in these associations is still controversial. 7 Monogenic diseases that cause hypertriglyceridemia are uncommon and arise from defects in the peripheral catabolism of triglyceride-rich lipoproteins as a result of mutations in the genes coding for lipoprotein lipase (LPL); its cofactor, the apolipoprotein (apo) CII (APOC2); a protein involved in lipase dimerization, lipase maturation factor 1 (LMF1); or glycosylphosphatidylinositol anchored high-density lipoproteinbinding protein 1 (GPIHBP1), which acts as a platform for lipoprotein lipase-mediated processing of chylomicrons. In addition, defects in the liver uptake of lipoprotein remnants associated with apo E variants are a cause of hypertriglyceridemia. 8 Except for rare severe mutations in APOE, 9 monogenic hypertriglyceridemia is autosomal recessive, suggesting that different gene products are involved in triglyceride metabolism that can functionally compensate for severe defects in heterozygosis. The vast majority of primary hypertriglyceridemia is diagnosed as familial combined hyperlipidemia (FCHL), familial hypertriglyceridemia, or sporadic hypertriglyceridemia. 8, 10 These diseases are highly heterogeneous and of unknown cause but share some clinical characteristics among them. In most cases, 11 they are complex diseases involving an important interaction of polygenes with environmental factors. 8, 10 Different association studies, mainly genome-wide association studies, have localized common DNA sequence variants that contribute to blood triglyceride concentration. 12, 13 Each variant confers a modest effect, and together, the variants explained only a small fraction of interindividual variability in blood triglycerides. An effect of polymorphism on triglyceride levels is correlated with the magnitude of its effect on coronary artery disease risk.
14 Most of the information on this previously reported genetic association comes from large observational studies in the general population in which normal interindividual variability in triglycerides could be analyzed. However, few studies have been performed that have explored the contribution of common genetic variants in patients with primary hypertriglyceridemia; in most cases; the studies have been limited to a small number of loci. 15 Identification of these genetic loci would point to possible mechanisms leading to hypertriglyceridemia, which may contribute to a better diagnosis and treatment of this condition. Hence, the objective of this study was to identify the contribution to primary hypertriglyceridemia of common genetic variants that have previously been associated with blood triglyceride concentration in the general population and to identify potential genetic differences between FCHL and primary isolated hypertriglyceridemia.
Materials and Methods

Study Participants
Cases
From January 2006 to April 2012, all consecutive unrelated patients aged ≥18 years with hypertriglyceridemia attending our lipid clinic were recruited for this study. Hypertriglyceridemia was considered when, ≥1 of 2 consecutive lipid measurements after 5 weeks of a lipid-lowering diet and without alcohol consumption still showed triglyceride levels >200 mg/dL 16 or over the sex-and age-adjusted 90th percentile for the Spanish population. 17 Exclusion criteria were secondary hypertriglyceridemia, including severe obesity (body mass index [BMI] , ≥35 kg/m 2 ), poorly controlled type 2 diabetes mellitus (HbA1c≥8%), renal disease with filtration rate <30 mL/min, liver disease except for nonalcoholic fatty liver, and estrogen or oral steroid consumption. Also excluded from the study were patients with monogenic hypertriglyceridemia, including type III hyperlipoproteinemia resulting from a p.Arg146Ser mutation in APOE or the ɛ2/ɛ2 APOE genotype; those with type I hyperchylomicronemia defined as severe hypertriglyceridemia from childhood with a personal history of pancreatitis; and those with HFE genotypes causing hemochromatosis were also excluded from this study. 18 The diagnosis of FCHL was based on the presence of primary combined hyperlipidemia with offtreatment serum cholesterol and triglycerides over the sex-and ageadjusted 90th percentile for the Spanish population, ≥1 first-degree relative with hyperlipidemia (total cholesterol and triglycerides >90th percentile for the Spanish population, ≥1 first-degree relative with hyperlipidemia) and serum total apo B levels ≥120 mg/dL. The diagnosis of familial hypertriglyceridemia was based on the presence of primary hypertriglyceridemia, with off-treatment triglycerides over the sex-and age-adjusted 90th percentile and serum total apo B levels <120 mg/dL and a family history of hyperlipidemia. The diagnosis of sporadic hypertriglyceridemia was based on the same criteria as familial hypertriglyceridemia but without a family history of hyperlipidemia. Therefore, familial hypertriglyceridemia and sporadic hypertriglyceridemia patients were considered for further analysis as a unique group of isolated hypertriglyceridemia.
Controls
The control group consisted of normolipidemic participants (<90th percentile for total cholesterol and triglycerides). They were unrelated volunteers, men and women, who underwent a routine medical examination in our hospital and have been partially described elsewhere. 19 Written informed consent was obtained from all patients and controls, and the study protocol was approved by our institutions ethical committee.
Clinical and Laboratory Determinations
All participants were assessed for family history of early onset coronary heart disease, personal medical history, medication use, demographic characteristics, adiposity measures, and cardiovascular risk factors. The procedure to check the family history of hyperlipidemia was either by direct blood analysis in our institution or reviewing the medical record at our institution. Diabetes mellitus was defined as a fasting glucose level ≥126 mg/dL or current treatment with antidiabetic drugs. Fasting blood for baseline biochemical profiles was drawn after ≥5 weeks after a lipid-lowering diet and without lipidlowering drugs. Apo AI, apo B, and lipoprotein(a) (Lp(a)) were determined using a rate nephelometric immunochemistry assay by Image System (Beckman Coulter).
Genotyping
DNA was isolated from EDTA-exposed blood samples following standard protocols. Thirty-seven single nucleotide polymorphisms (SNPs) were genotyped by iPlex technology based on a MassARRAY platform (Sequenom, Valencia, Spain). The SNPs and genes were as follows: rs2230806 in ABCA1; rs767870 and rs929434 in ADIPOR2; rs1042713 in ADRB2; rs1748195 and rs1213033 in ANGPTL3; rs3135506 and rs662799 in APOA5; rs693 in APOB; rs7412 and rs429358 in APOE; rs2569190 in CD14; rs708272 in CETP; rs3808607 in CYP7A1; rs3760158 in DGK3; rs1799883 in FABP2; rs174547 in FADS3; rs4846914 in GALNT2; rs1260326 in GCKR; rs1800795 in IL6; rs2721 in INSIG; rs268, rs328, rs1801177, and rs7007797 in LPL; rs17145738 and rs3812316 in MLXIPL; rs1800591 in MTTP; rs16139 in NPYN; rs1800206 in PPARA; rs16996148 in PBX4; rs28359554 in PCK1; rs2293869 in RP1; rs7849 in SCD1; rs79031410 in TCF7L2; rs17321515 in TRIB1; and rs3737787 in USF1. SNPs selection was based on previously reported association studies with hypertriglyceridemia.
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Statistical Analyses
All statistical analyses were performed using the SPSS software v.20 (SPSS Inc, Chicago, IL) except where noted. Data are presented as mean±SD for continuous variables, as median and interquartile range for variables with a skewed distribution, and as a frequency or percentage for categorical variables. Differences in mean values were assessed using t tests or the Mann-Whitney U test, as appropriate. Categorical variables were compared using the χ 2 test. To study the possible associations of SNPs and the hypertriglyceridemia phenotype, odds ratios (ORs) were calculated by bivariate logistic regression using study group (hypertriglyceridemia versus control) as the dependent variable; as the independent variables, each one of the SNPs were considered independently that was significant when comparing genotype distribution between patients with hypertriglyceridemia and controls, considering the homozygosis status as indicators for the major allele. To study the inheritance model of these variants, additive, dominant, and recessive genetic models were explored using HelixTree SNP and Variation Suite Genetic Analysis Software version 6.4.2 (Golden Helix, Bozeman, MT). Testing in the additive model intends to reveal additive associations of the minor allele. The dominant model specifically tests the association of having ≥1 minor allele versus not having any at all. Testing in the recessive model is designed to detect the association of having the homozygous genotype for the minor allele versus having ≥1 major allele. Correlation tests gave a P value for the dependent variable, plasma triglyceride concentration, for any correlation with the count value of the genotype, according to the inheritance model. 20 Bonferroni correction was applied in every case. 21 The best inheritance model was chosen based on the correlation (R) with triglyceride levels and P values, as calculated by HelixTree SNP and Variation Suite Genetic Analysis Software version 6.4.2 (Golden Helix). In every case, the inheritance model with the lowest significant P value was chosen.
Only significant SNPs and clinical variables that are well known to influence plasma triglyceride concentration were used as explanatory variables for multiple binary logistic regression analysis using the method stepwise. When several SNPs within the same locus were analyzed, associations based on minor alleles were built and analyzed according to the inheritance model previously established by the analysis with Helixtree Software. If positive, the association was used for binary logistic regression, instead of individual SNPs. The study group (hypertriglyceridemia versus control) was used as the dependent variable, and age, sex, BMI, blood glucose; presence of any ADIPOR2 rs929434 minor allele (yes/no); minor allele homozygosity for ANGPTL3 rs1748195, GALNT rs4846914, and GCKR rs1260326 (yes/no); number of minor alleles of APOA5 rs662799 and rs3135506 and presence of any minor allele of rs328 or rs7007797 in LPL (yes/no) were considered as independent variables.
Results
Clinical and biochemical characteristics of the 580 participants with hypertriglyceridemia and 403 controls are listed in Table 1 . Percentage of men, waist circumference, and BMI values were higher in the hypertriglyceridemia group than in the control group. Also, hypertriglyceridemia participants presented higher levels of glucose, total cholesterol, triglycerides, and apo B and lower concentrations of high-density lipoprotein cholesterol, Lp(a), and apo AI than controls.
All genotype frequencies apart from rs3808607 in CYP7A1, rs1800795 in IL6, and rs17321515 in TRIB1 were compatible with Hardy-Weinberg expectations. The allelic frequencies observed in controls in this study were compared with the European population in 1000 Genomes Project, and only differences in CYP7A1 and IL6 were observed. 22 CYP7A1, IL6, and TRIB1 were excluded from the hypertriglyceridemia model because of these data.
To identify potential differences in the genetic background associated with hypertriglyceridemia of isolated hypertriglyceridemia and FCHL, the allelic frequencies were compared between participants classified according to these phenotypes. Five variants showed statistically significant differences in the distribution within these groups (Table 2) : rs7412 in APOE and rs1800795 in IL6 were more frequent in isolated hypertriglyceridemia individuals (P<0.05); and rs3808607 in CYP7A1 and rs3812316 and rs17145738 in MLXIPL were more frequent in FCHL participants (P<0.05). According to these results, the isolated hypertriglyceridemia and FCHL groups seemed to be homogeneous, and further analysis were performed combining both groups into 1 designated as hypertriglyceridemia.
Of 37 SNPs, 10 showed significant allelic and genotype frequency differences between hypertriglyceridemia and control groups (Table 3 ). In addition, SNPs rs929434 and rs1800795 showed only genotype differences only between groups (Table I in the Data Supplement). Those 12 SNPs were located in 10 different genes: ADIPOR2, ANGPTL3, APOA5, APOE, GALNT2N, GCKR, LPL, IL6, TCF7L2, and TRIB1. For these 12 significant SNPs, the ORs were determined by bivariate logistic regression using study group (hypertriglyceridemia versus control) as the dependent variable; independent variables were the status of being heterozygous or homozygous for the minor allele against being homozygous for the major allele in each variant considering those separately (Table 4) . With these analyses, P values for the SNPs in IL6 and TCF7L2 were not significant or were inconclusive. For ADIPOR2, ANGPTL3, LPL, and TRIB1 variants, the ORs and P values observed in heterozygotes and minor allele homozygotes were <1 and <0.05, respectively; thus the minor allele carriers showed protection for hypertriglyceridemia, although for ANGPTL3, a double dose of the rare allele was needed to show protection for hypertriglyceridemia. By contrast, minor alleles of APOE, APOA5, GALNT2N, and GCKR showed ORs>1 and were associated with hypertriglyceridemia (P<0.05). The association was especially important for the 2 SNPs analyzed in APOA5, with OR=12.96 and 5.59 for homozygotes for rs3135506 and rs662799, respectively. The genetic model of inheritance was tested with the Helixtree software ( Table 5 ). A recessive model of inheritance was observed for SNPs in ANPGTL3, GALNT2N, and GCKR, whereas LPL and ADIPOR2 fit a dominant model, and APOA5 an additive one. Table 6 shows the results of binary logistic regression analysis using study group (hypertriglyceridemia versus control) as the dependent variable. The variables that were independently associated with hypertriglyceridemia were BMI, glucose, sex, LPL rs328 and rs7007797, the APOA5 rs662799 and rs3135506, and GCKR rs1260326. Taken together and in this order, the adjusted R 2 was 0.361 (P<0.001). Within this model, the contribution of genetic variants LPL, APOA5, and GCKR explained the 7.3% of the presence of hypertriglyceridemia. The Figure shows the triglycerides concentration according to the amount of the positively associated alleles minus the number of LPL protective alleles. We have observed that the higher the value of the sum, the greater the level of triglycerides.
When hypertriglyceridemia participants were divided according to baseline triglycerides concentration (>500 or <500 mg/dL), only the APOA5 rs3135506 (P<0.001) and APOE rs7412 SNPs (P<0.05) showed significant higher frequencies (0.208 versus 0.125 and 0.103 versus 0.059) of the minor allele in those with triglycerides >500 mg/dL (data not shown). Moreover, there were no differences in allele frequency when hypertriglyceridemia individuals were classified into 2 groups by BMI (>28 or <28 kg/m 2 ; data not shown).
Discussion
Several conclusions can be derived from our work, in which we have analyzed 230 patients with isolated hypertriglyceridemia, 350 with FCHL, and 403 controls, constituting the largest population to date with these phenotypes genotyped for 37 SNPs previously associated with triglyceride levels. 13, 23 First, the majority of the SNPs associated with hypertriglyceridemia were found with the same frequency in isolated hypertriglyceridemia and FCHL. Although some of these were more frequent in the isolated hypertriglyceridemia group and other in FCHL, none of them seemed to have enough power to be used as discriminatory between phenotypes. It has recently been proposed that FCHL is a compendium of multiple defects that can be different among families: dysfunctional adipose tissue, hepatic fat and very low-density lipoprotein overproduction, triglyceriderich lipoprotein metabolism, and clearance of low-density lipoprotein particles. 24 Therefore, the common genetic background that we have found between isolated hypertriglyceridemia and FCHL could reflect that both entities would share metabolic defects, in which triglyceride levels would be a secondary phenomenon. The SNPs in CYP7A1 and MLXIPL that were more frequent in FCHL than in isolated hypertriglyceridemia patients are located in loci previously associated with cholesterol metabolism.
13 CYP7A1 has been linked to total and low-density lipoprotein cholesterol 13 and MLXIPL to high-density lipoprotein cholesterol, in both cases by unknown mechanisms. 13, 25, 26 Our results suggest that most cases of FCHL and isolated hypertriglyceridemia are polygenic diseases sharing a similar genetic background with an accumulation of certain common and, probably, some rare genetic variants. 9 We have observed a higher frequency of the APOE SNP rs7412 in isolated hypertriglyceridemia patients, as expected. This polymorphism is causal of the Apo E isoform ε2, associated with higher level of triglycerides. The rs3737787 SNP in USF1 has been classically associated with FCHL and confers increased risk for FCHL by regulating a group of genes Homozygosity for rs7412 (APOE ɛ2/ɛ2) was an exclusion criteria. To study the possible associations of SNPs and the hypertriglyceridemia phenotype, odds ratios were calculated by bivariate logistic regression using study group (hypertriglyceridemia versus control) as the dependent variable; as the independent variables, each one of the SNPs were considered independently that was significant when comparing genotype distribution between patients with hypertriglyceridemia and controls. The homozygosis status for the major allele was considered as indicator for each variant. CI indicates confidence interval; OR, odds ratio; and HTG, hypertriglyceridemias. R shows the correlation between triglycerides concentration and the count value of the genotype according to the inheritance model. P value was calculated with correlation test and Bonferroni correction was applied in every case. The best inheritance model was chosen based on the correlation (R) with triglyceride levels and P values. SNP indicates single nucleotide polymorphism. †The variables APOA5 rs662799 and APOA5 rs3135506 are defined by the presence of 1 (Het.) or 2 minor (minor hom.) alleles (additive model of inheritance).
‡The variable GCKR rs1260326 is defined by the presence of the minor homozygote (recessive model of inheritance).
that contributes, in part, to increased triglyceride levels. 27 Included in this group are genes related to lipid phenotypes, atherogenic processes, and reactive oxygen species, which can be the cause of this tendency to a difference in rs3737787 allele frequency in isolated hypertriglyceridemia and FCHL. According to this and previous studies, FCHL brings together SNPs predisposing to polygenic hypercholesterolemia in addition to those associated with triglycerides. The near-statistical significance observed for the SNPs rs268 and rs328 in the LPL gene suggests its relationship with the triglyceride levels, which is considered a key component trait for FCHL. Those SNPs, which are sited in different linkage disequilibrium blocks, have opposite effects on triglyceride levels as has been shown here and in previous study. 28 Hence, FCHL is probably a combination of polygenic hypercholesterolemia and polygenic hypertriglyceridemia.
Only some gene variants that contribute to interindividual variation in triglycerides in the general population are differentially found in primary hypertriglyceridemia. According to our results, the genetic contribution to the hypertriglyceridemia phenotype is mainly based on 5 SNPs in 3 genes: rs328 and rs77007797 in LPL, rs662799 and rs3135506 in APOA5, and rs1260326 in GCKR. This outcome is in accordance with the results observed in genome-wide association studies, in which the APOA1-C3-A4-A5 locus, LPL, and GCKR genes have the strongest effect sizes for triglyceride levels (effect sizes of +16.95, −13.64, and +8.76 mg/dL). 13 Our findings suggest that only those SNPs with the highest effect on triglyceride levels in the general population are clinically useful in explaining the genetic component of primary hypertriglyceridemia.
Most primary hypertriglyceridemia seems to be the result of accumulation within certain individuals of common variants with only modest effects on the triglyceride concentration. These common variants are individually associated with hypertriglyceridemia, and together with BMI and sex, would explain ≈36% of triglycerides variation. A previous study in a population with a more severe hypertriglyceridemia than ours had shown that genetic variants in 7 loci and clinical variables explained ≈40% of triglyceride variation. 29, 30 We found a similar percentage in our study.
LPL, APOA5, and GCKR are closely related to hypertriglyceridemia and should be considered as risk factors for this lipid abnormality. The LPL variants have been associated with lipoprotein lipase deficiency leading to an increase in triglyceride levels. 10 The mechanism of association between APOA5 and triglycerides is still unknown; however, apo AV protein levels are consistently associated with high triglyceride, 31 and apo AV can interact with lipoprotein lipase, proteoglycans, and GPIHBP1, suggesting that it facilitates triglyceride hydrolysis. 32 The glucokinase regulatory protein encoded by GCKR is an allosteric regulator that allows rapid mobilization of glucokinase in response to glucose concentrations. The rs1260326 SNP produces a functional variant (p.Pro446Leu) that promotes glucose uptake and mobilization, leading to an increase in de novo triglyceride synthesis. 24, 33 Another interesting feature of our work is the different inheritance model of the associated SNPs with hypertriglyceridemia. Only homozygosity for the minor allele of GCKR was independently associated with hypertriglyceridemia, in contrast with the dominant model of LPL or the additive model of APOA5. Taking into account the inheritance model, the association was highly improved when all pathogenic alleles were considered together (Figure) .
One limitation of our study is that our population was from a single center and was highly uniform with respect to their genetic background. Therefore, the genetic associations found in this work may not apply to other populations. We did not excluded participants with nonsevere obesity, which could be Number of pathogenic alleles of APOA5 and GCKR considering the alleles of the minor alleles of rs328 and rs7007797 in LPL as protectors for high triglyceride levels. A, Control subjects, (B) hypertriglyceridemic subjects, (C) all study subjects. The number of pathogenic alleles was calculated as the sum of the positively associated alleles of the SNPs: rs662799 and rs3135506 in APOA5 and rs1260326 in GCKR minus the one when the subjects were carriers of one of the minor and protective alleles of the SNPs rs328 and rs7007797 in LPL. Triglycerides levels were expressed as milligrams per deciliter in all study subjects. The difference in triglycerides levels between the groups was calculated by ANOVA test. a limitation because of the close relationship between triglycerides and adiposity; however, we did not observe any differences in the genetic association between obese and nonobese participants. Thus, we think that our results would not be affected by a selection of nonobese participants, and we might consider the effect of being overweight as mostly independent of the studied genetic factors.
In contrast with a previous study, 29, 30 we have considered mild hypertriglyceridemia (triglyceride levels >200 mg/dL) to include isolated hypertriglyceridemia and FCHL. Johansen et al 29 studied 504 participants with triglycerides >500 mg/dL. In spite of the difference between triglyceride levels between the studies, the associated genes and the genetic contribution to hypertriglyceridemia were almost the same, probably indicating that those genes interfere in complex metabolic pathways in which the high triglyceride level is not the main metabolic defect. 23 In conclusion, our results suggest that common genetic variants found in the general population are responsible for high triglyceride levels in patients with primary hypertriglyceridemia. FCHL and isolated hypertriglyceridemia share many genetic variants and are probably the result of the additive effect of several genetic variants predisposing to hypertriglyceridemia in the case of familial and sporadic hypertriglyceridemias and predisposing to hypertriglyceridemias and hypercholesterolemia in the case of FCHL. 
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